The topic of family presence (FP) during cardiopulmonary resuscitation or invasive procedures has recently received attention and debate among healthcare professionals due to pioneering research in this field. Studies completed have included family perspectives on family presence, patients' feelings on family presence, and healthcare providers' views on family presence. Two key areas found to correlate with family presence acceptance among healthcare providers are education and experience. Senior nursing students in one baccalaureate program were introduced to this topic during a 3-hour class on death and dying. Comparisons between pretest and posttest scores revealed an increase in the acceptance of family presence as a priority in nursing care of the critically ill.
A489 Objectives: As the emphasis on value of oncology agents grows, ASCO has released a framework proposing to evaluate the net health benefit of such therapies. This study aims to evaluate the application of the ASCO framework for all recently approved oncology therapies, including barriers and challenges that may be encountered. MethOds: Oncology drugs approved from January 2013 to May 2015 (N= 19) were obtained from the FDA website. Palliative therapies were excluded. Registrational trials (N= 31) for the corresponding drugs were identified from peer-reviewed publications. The Net Health Benefit (NHB) score worksheet was completed for each clinical trial as outlined in the ASCO advanced disease framework using Overall Survival (OS), Progression-Free Survival (PFS), Response Rate (RR), Toxicity, Palliation, and Treatment-Free Interval. Issues encountered were catalogued for review. Results: 1 of 31 clinical trials was excluded due to lack of publication in peer-reviewed journals. An additional 9 trials were excluded due to non-randomized trial design, resulting in 22 trials corresponding to 16 drugs. OS data was used for scoring in 59% of the remaining trials. PFS was used in 27% of the trials, and RR in 14% of the trials. Toxicity data was scored in 95% of the trials, palliation data in 77% of trials, and treatment-free interval data in 95% of the trials. The most common scoring issues encountered included median OS or PFS not reached (8/22) and incomplete palliation or treatment-free interval data (5/22). cOnclusiOns: Lack of peer-reviewed publications, non-randomized trial designs, and requisite clinical data resulted in methodological challenges that deterred application of the ASCO framework for recent oncology drugs. Lack of appropriate data may result in lower scores than could be recognized from the available evidence at time of market authorization.
CORRIGENDUM RESULTS BY EXPOSURESF5.3. Beverages. The associations between food, nutrition, physical activity, and the risk of weight gain, overweight and obesity: a systematic review of the epidemiological evidence
Correspondenceto extremely low concentrations and the hypomethioninaemia persisted for several days (unpublished observation). A possible explanation for this unexpected result lies in the fact that methionine metabolism is influenced, and in opposite directions, by both methylcobalamin and by adenosylcobalamin, the former through the methionine synthetase reaction which increases the serum
JSTOR is a not-for-profit service that helps scholars, researchers, and students discover, use, and build upon a wide range of content in a trusted digital archive. We use information technology and tools to increase productivity and facilitate new forms of scholarship. For more information about JSTOR, please contact support@jstor.org.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.